关于这一集
Get it? Attractive? Magnets. Yeh, we’ll, we’re tired from putting this monster podcast episode together but it’s so, so good.
You’ll hear from David Fischel, CEO of Stereotaxis, a 30-plus year old medtech that’s going through a quiet but deliberate reboot. Fischel says he took the company over because Stereotaxis’ magnetic robotic surgery system makes interventional surgery safer, an assertion supported by Daniel Cooper, MD, associate professor at Washington University School of Medicine. Stereotaxis appears to be on the cusp of something big.
Then, Alberto Rodriguez-Navarro, MD, tells us why he sold everything to move from his native Chile to move to Silicon Valley and start Levitra Magnetics. The company is anticipating FDA approval for its own robotic system that could help hospitals overcome staffing shortages during laparoscopic procedures.
We’ll also hear our sponsor Futek explain how its miniaturized sensors are advancing robotic surgery.
Chris Newmarker, executive editor of life sciences, delivers the week’s big news featuring Siemen Healthineers, LumiraDx, Boston Scientific, Abbott and Medtronic. Senior editor Danielle Kirsh updates us on the Theranos trial.
Subscribe to this podcast on all major channels.
You’ll hear from David Fischel, CEO of Stereotaxis, a 30-plus year old medtech that’s going through a quiet but deliberate reboot. Fischel says he took the company over because Stereotaxis’ magnetic robotic surgery system makes interventional surgery safer, an assertion supported by Daniel Cooper, MD, associate professor at Washington University School of Medicine. Stereotaxis appears to be on the cusp of something big.
Then, Alberto Rodriguez-Navarro, MD, tells us why he sold everything to move from his native Chile to move to Silicon Valley and start Levitra Magnetics. The company is anticipating FDA approval for its own robotic system that could help hospitals overcome staffing shortages during laparoscopic procedures.
We’ll also hear our sponsor Futek explain how its miniaturized sensors are advancing robotic surgery.
Chris Newmarker, executive editor of life sciences, delivers the week’s big news featuring Siemen Healthineers, LumiraDx, Boston Scientific, Abbott and Medtronic. Senior editor Danielle Kirsh updates us on the Theranos trial.
Subscribe to this podcast on all major channels.
英语
美国
文字稿 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
本播客中的其他单集
In this episode of the DeviceTalks Weekly podcast, we tackle a range of topics related to the surgical robotics industry. In our keynote conversation, Brian Miller, formerly of Intuitive and now CEO of Sovato, discusses the potential of telesurgery, a promising capability of surgical robotic syst...
In this episode of the DeviceTalks Weekly Podcast, Managing Editor Kayleen Brown sits down with Johnson & Johnson MedTech Heart Recovery Worldwide President Devi Govender at DeviceTalks Boston.
Govender shares how a deeply personal family experience shaped her mission to transform cardiovasc...
In this episode of DeviceTalks Weekly, Host Tom explores the breakthrough technologies—and the unique culture—driving one of MedTech's most ambitious missions with XCATH CEO Eduardo Fonseca. The conversation goes well beyond robotics. Fonseca explains why XCATH hires for humility as much as talen...
In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi is joined by Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health. Dr. Rajagopalan explains why Fractyl shifted its focus from treating type 2 diabetes to helping former GLP-1 users maintain their weight loss with Rev...
In this episode of the DeviceTalks Weekly Podcast, host Tom Salemi is reassured by his conversation with Joe Catanese, CEO of Calyxo, a urology startup that has developed a system designed to simplify kidney stone removal.
Catanese previously helped build Neotract, a urology startup that was acq...
免责声明: 本页面嵌入的播客和封面图片来自 DeviceTalks Podcast Network，归其所有者所有，与 Listen Notes, Inc. 无关联，也未获得 Listen Notes, Inc. 背书。
